Maas Biolab, Inc.

Albuquerque, NM 87106

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $2.13MM
First Award Date 09/30/07
Most Recent Award Date 01/01/10

Key Personnel

Last Name Name Awards Contact
Karlsson Jenny Karlsson 4

4 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-06-005
Budget: 01/01/10 - 08/31/13

DESCRIPTION (provided by applicant): The scientific research proposed, the determination of pre-clinical stability, pharmacokinetics and toxicology testing of Maas BiolAB's proprietary cyclosporin intrathecal formulation, Mitogard(tm), will allow the company to file for Investigational New Drug (IND) approval with the Food and Drug Administratio...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-06-005
Budget: 09/01/08 - 12/31/09

DESCRIPTION (provided by applicant): The scientific research proposed, the determination of pre-clinical stability, pharmacokinetics and toxicology testing of Maas BiolAB's proprietary cyclosporin intrathecal formulation, Mitogard(tm), will allow the company to file for Investigational New Drug (IND) approval with the Food and Drug Administratio...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-06-005
Budget: 09/01/08 - 08/31/09

DESCRIPTION (provided by applicant): The scientific research proposed, the determination of pre-clinical stability, pharmacokinetics and toxicology testing of Maas BiolAB's proprietary cyclosporin intrathecal formulation, Mitogard(tm), will allow the company to file for Investigational New Drug (IND) approval with the Food and Drug Administratio...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-06-005
Budget: 09/30/07 - 08/31/08

DESCRIPTION (provided by applicant): The scientific research proposed, the determination of pre-clinical stability, pharmacokinetics and toxicology testing of Maas BiolAB's proprietary cyclosporin intrathecal formulation, Mitogard(tm), will allow the company to file for Investigational New Drug (IND) approval with the Food and Drug Administratio...